To the Editor.—Of primary concern was the patient selection. During the 15-year period reported, six therapeutic programs evolved. Each program was designed by the chiefs of surgery and radiology for the time periods stated and established by the Hospital Tumor Board irrespective of the individual patient. Adherence to the design of the program was consistent. The indication for postsurgical radiation therapy from 1948 through 1956 was the presence or absence of microscopically proven axillary lymph node metastases. Beginning in 1957 and through this series, each patient upon whom a radical mastectomy was performed received postsurgical radiation therapy. The 250-kv radiation therapy used initially was replaced by radioactive cobalt (60Co) therapy in June 1957. The cobalt therapy was 5,000 rads to the axillary, supraclavicular, and mediastinal areas. The 250-kv dosage was calculated for each patient to achieve cancericidal level. From 1957 through this series, one individual served as head
GETZEN LC. COMMENTS ON GETZEN ET AL'S ARTICLE-Reply. Arch Surg. 1969;99(3):418–420. doi:10.1001/archsurg.1969.01340150126029
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: